EuroBiotech: More Articles of Note

(NS Newsflash/CC BY 2.0)

> Shares in one of Neil Woodford’s funds fell 10% after Prothena reported the failure of a phase 2b trial. Woodford bet big on Prothena but, as with some of his previous investments including Circassia, has been stung. A statement by Woodford about the Prothena data was flooded with comments from investors questioning his approach. Statement

> Sofinnova Partners led a €26.5 million ($32.3 million) investment in EryDel. The Italian biotech will use the money to fund a phase 3 trial of its red-blood-cell-based drug delivery system. Release 

> Redx Pharma named Lisa Anson as its CEO. Anson, the former president of AstraZeneca in the U.K., arrives at Redx as it seeks to bounce back from financial troubles. Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Autolus licensed a clinical-stage CD19 CAR-T therapy. The candidate is designed to improve on first-generation CD19 CAR-Ts by reducing side effects related to cytokine release syndrome. Release

> Boehringer Ingelheim entered into an antigen-specific tolerance induction collaboration with Topas Therapeutics. The agreement gives Boehringer an option to license preclinical candidates discovered in the collaboration. Statement 

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.